Cargando…

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)

Detalles Bibliográficos
Autores principales:	Boyerinas, Benjamin, Tucker, Jo A, Poole, Diane J, Jochéms, Caroline, Palena, Claudia, Schlom, Jeffrey, Tsang, Kwong Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991360/ http://dx.doi.org/10.1186/2051-1426-1-S1-P202

Ejemplares similares

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
por: David, Justin M., et al.
Publicado: (2016)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer
por: XU, KE, et al.
Publicado: (2015)

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies
por: Huang, B, et al.
Publicado: (2013)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
por: Palena, Claudia, et al.
Publicado: (2010)

Glycan Epitope and Integrin Expression Dynamics Characterize Neural Crest Epithelial-to-Mesenchymal Transition (EMT) in Human Pluripotent Stem Cell Differentiation
por: Thomas, Ria, et al.
Publicado: (2022)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma
por: Du, Rui, et al.
Publicado: (2014)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Brachyury engineers cardiac repair competent stem cells
por: Li, Mark, et al.
Publicado: (2020)

Brachyury identifies a class of enteroendocrine cells in normal human intestinal crypts and colorectal cancer
por: Jezkova, Jana, et al.
Publicado: (2016)

The T-box transcription factor Brachyury regulates epithelial–mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells
por: Shimoda, Miyuki, et al.
Publicado: (2012)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017)

Genomic Targets of Brachyury (T) in Differentiating Mouse Embryonic Stem Cells
por: Evans, Amanda L., et al.
Publicado: (2012)

T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma
por: IMAJYO, IKUMI, et al.
Publicado: (2012)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT)
por: Kasai, Hidenori, et al.
Publicado: (2005)

Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics
por: Lee, Kwan Ho, et al.
Publicado: (2018)

Geometrical confinement controls the asymmetric patterning of brachyury in cultures of pluripotent cells
por: Blin, Guillaume, et al.
Publicado: (2018)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Quantitative Dissection of the Proximal Ciona brachyury Enhancer
por: Shimai, Kotaro, et al.
Publicado: (2022)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
por: Dominguez, Charli, et al.
Publicado: (2016)

Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas
por: Fernando, Romaine I, et al.
Publicado: (2013)

BRACHYURY and CDX2 Mediate BMP-Induced Differentiation of Human and Mouse Pluripotent Stem Cells into Embryonic and Extraembryonic Lineages
por: Bernardo, Andreia S., et al.
Publicado: (2011)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

Epithelial–Mesenchymal Transition (EMT)
por: Manfioletti, Guidalberto, et al.
Publicado: (2023)

Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells
por: Rahmani Barouji, Solmaz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_arb17uoepkpctap574cqb9oajr